Sensars
Lausanne · Founded 2014
About Sensars
Sensars is a medtech start-up developing implantable neuroprosthetics for diabetic neuropathy complications such as diabetic foot ulcers, amputation and falls prevention and neuropathic pain treatment. Our flagship system, SENSY, restores natural foot sensation in patients with diabetes, sensory loss, or prosthetic limbs using neuromodulation and AI-driven gait analysis. By restoring sensation, SENSY prevents ulcers, amputations, falls, and chronic pain, improving patient survival and independence. Backed by FDA Breakthrough Device Designation, strong IP, and peer-reviewed clinical data, Sensars addresses a massive unmet need in diabetic foot care.
Company Facts
- Founded: 2014
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $4.8M
- Funding stage: Seed
- Last round: Seed (Sep 2025)
- Website: https://www.sensars.com/
- Phone: +41 762-32-42-55
Industries & Categories
Diabetes, Health Care, Medical, Medical Device, Neuroscience
Social Profiles
Canonical: https://fsome.com/organization/sensars-14416 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.